Skip to Content
Global News Select

Becton Dickinson 1Q Profit Rises on Covid-19 Testing

By Dave Sebastian

 

Becton, Dickinson & Co. said sales of products used for Covid-19 testing and prevention drove its profit up for the fiscal first quarter.

The New Jersey-based medical-technology company Thursday posted net income of $1 billion, compared with $278 million in the prior year.

Earnings were $3.35 a share, compared with 87 cents a share a year earlier.

Adjusted earnings were $4.55 a share. Analysts polled by FactSet were looking for $3.12 a share.

Revenue was $5.32 billion, up 25.8% from the same period a year ago, matching its expectations. Analysts were looking for $4.92 billion.

Covid-19 testing sales were $867 million for the quarter.

Sales in its medical segment grew 8.2% to $2.26 billion due to higher demand for products used in the treatment and prevention of Covid-19, such as prefillable syringes. Life-sciences sales grew 76.2% to $1.98 billion, the company said

Revenue in its biosciences unit fell as the prior year's benefit of licensing revenue eclipsed gains from research and clinical-lab activity and Covid-19 vaccine research. International sales rose 6.2% to $1.08 billion as practitioners worked through patient backlogs for elective care.

 

Write to Dave Sebastian at dave.sebastian@wsj.com

 

(END) Dow Jones Newswires

February 04, 2021 06:42 ET (11:42 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.